Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were
recognized as the genetic code containing the necessary information for proper cell …

Renal cell carcinoma (RCC) is the most common type of urogenital cancer. It has a mortality
rate of 30-40% and is more commonly seen in men than women. In addition to gender, other …

Renal cell carcinoma (RCC) is a malignant tumor of the kidneys. Approximately 70% of RCC
cases are clear cell renal cell carcinoma with von Hippel–Lindau (VHL) gene mutation and …

Simple Summary Physicians routinely make individualized treatment decisions by
accounting for the joint effects of patient prognostic covariates and treatments on clinical …

Background The tumor microenvironment (TME) and tertiary lymphoid structures (TLS) affect
the occurrence and development of cancers. How the immune contexture interacts with the …

The prognosis for advanced clear cell renal cell carcinoma (ccRCC) is not satisfactory, even
though its treatment has evolved rapidly over the past 20 years. Systemic ccRCC treatment …

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors
worldwide. The clinical treatment of ccRCC is strongly associated with the tumor …

Targeting tumor-associated angiogenesis is currently at the forefront of renal cell carcinoma
(RCC) therapy, with sunitinib and bevacizumab leading to increased survival in patients with …

Background The transient receptor potential vanilloid (TRPV) channels family, TRPV1-6, has
been identified to profoundly affect a wide spectrum of pathological processes in various …

RNA molecules have emerged as promising clinical therapeutics due to their ability to
target" undruggable" proteins or molecules with high precision and minimal side effects …